Evaluating the costs for incorporating a new insulin in Brazil
| May 22, 2016
Evaluating the cost for incorporating insulin degludec in treating patients with diabetes mellitus is the theme of two posters that Evidências - Kantar Health will present at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The event takes place in Washington, D.C., May 21-25.
In Brazil few studies exist on insulin degludec – an ultra-long-acting basal insulin analog that covers the basal insulin requirements of patients. Our posters assess the budgetary impact that incorporating insulin degludec would have both in the public and private healthcare systems. The studies compare the costs of insulin degludec with insulin glargine, another ultra-long-acting basal insulin analog already marketed in Brazil.
“This type of analysis is very important to guide health decisions. Diabetes is a very common disease and represents a high cost to health systems, so evaluating the costs linked to new and old treatments is essential for informed decision-making,” says Alexandra Piedade, pharmacoeconomics analyst from Evidências - Kantar Health and one of authors of the study.
ISPOR is one of the most important scientific dissemination channels of pharmacoeconomics and outcomes research. Besides being a public non-profit organization for educational and scientific purposes, ISPOR promotes pharmacoeconomics science and the outcomes research, and facilitates the translation of this research into useful information for decision makers in the area of healthcare. The company has more than 9,500 members in 114 countries. ISPOR promotes three meetings annually, conducted in North America, Europe and Latin America or Asia.